ES2172195T3 - Inhibicion de la cristalizacion en dispositivos transdermales. - Google Patents

Inhibicion de la cristalizacion en dispositivos transdermales.

Info

Publication number
ES2172195T3
ES2172195T3 ES98944097T ES98944097T ES2172195T3 ES 2172195 T3 ES2172195 T3 ES 2172195T3 ES 98944097 T ES98944097 T ES 98944097T ES 98944097 T ES98944097 T ES 98944097T ES 2172195 T3 ES2172195 T3 ES 2172195T3
Authority
ES
Spain
Prior art keywords
drug component
active drug
active
matrix
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98944097T
Other languages
English (en)
Inventor
Fabian Isaac Biali
Alejandro Fabio Scasso
Francisco Jose Evarist Stefano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Technologies SA
Original Assignee
Amarin Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Technologies SA filed Critical Amarin Technologies SA
Application granted granted Critical
Publication of ES2172195T3 publication Critical patent/ES2172195T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Procedimiento de preparación de un dispositivo de administración transdermal que incluye las etapas de preparación de la mezcla de un componente de fármaco activo en cantidad suficiente para tener un efecto farmacéutico o fisiológico en la utilización del dispositivo y un material que forma la matriz, y disponiendo dicha mezcla en o sobre un soporte para formar una matriz que contenga dicho componente de fármaco activo, siendo dicho componente de fármaco activo una fármaco de hormona activo o un conjunto de fármacos de hormonas activas, estando el procedimiento caracterizado por el paso de mezclar de al menos uno de los mencionados materiales que constituyen la matriz y dicho componente de fármaco activo con una cantidad medida de un esteroide, teniendo dicha cantidad medida un efecto de inhibición de la cristalización de dicho componente de fármaco activo al almacenar el dispositivo terminado y estando en una cantidad insuficiente para provocar un efecto farmacéutico o siológico significativo cuando se utiliza el dispositivo.
ES98944097T 1997-09-25 1998-09-24 Inhibicion de la cristalizacion en dispositivos transdermales. Expired - Lifetime ES2172195T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9720470.5A GB9720470D0 (en) 1997-09-25 1997-09-25 Inhibition of crystallization in transdermal devices

Publications (1)

Publication Number Publication Date
ES2172195T3 true ES2172195T3 (es) 2002-09-16

Family

ID=10819670

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98944097T Expired - Lifetime ES2172195T3 (es) 1997-09-25 1998-09-24 Inhibicion de la cristalizacion en dispositivos transdermales.

Country Status (8)

Country Link
US (1) US6465005B1 (es)
EP (1) EP1023055B1 (es)
AR (1) AR013520A1 (es)
BR (1) BR9812523A (es)
DE (1) DE69803592T2 (es)
ES (1) ES2172195T3 (es)
GB (1) GB9720470D0 (es)
WO (1) WO1999015156A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465004B1 (en) 1999-06-05 2002-10-15 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
EP1323431B1 (en) * 2000-08-03 2010-10-27 Antares Pharma IPL AG Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20020106402A1 (en) * 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
AU2002320038B2 (en) 2001-06-18 2007-07-05 Noven Pharmaceuticals, Inc. Enhanced drug delivery in transdermal systems
US20050058695A1 (en) * 2002-05-30 2005-03-17 Watson Pharmaccuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
WO2003101461A1 (en) * 2002-05-30 2003-12-11 Watson Pharmaceuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
JP5619337B2 (ja) 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
FR2895679B1 (fr) * 2005-12-29 2012-06-08 Pf Medicament Stabilisation de testosterone au sein de dispositifs transdermiques
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
WO2010042152A2 (en) * 2008-10-06 2010-04-15 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
IN2014DN03247A (es) * 2011-11-04 2015-05-22 Agile Therapeutics Inc
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
WO1989007951A1 (en) 1988-02-26 1989-09-08 Riker Laboratories, Incorporated Transdermal estradiol delivery system
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US4814168A (en) 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
IL92496A0 (en) 1988-12-01 1990-08-31 Schering Corp Compositions for transdermal delivery of estradiol
AR246186A1 (es) 1989-11-17 1994-07-29 Beta Pharm Co Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE4429664C2 (de) 1994-08-20 1997-09-11 Lohmann Therapie Syst Lts Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same

Also Published As

Publication number Publication date
EP1023055A1 (en) 2000-08-02
GB9720470D0 (en) 1997-11-26
DE69803592D1 (de) 2002-03-14
BR9812523A (pt) 2000-07-25
AR013520A1 (es) 2000-12-27
WO1999015156B1 (en) 1999-06-10
WO1999015156A1 (en) 1999-04-01
DE69803592T2 (de) 2002-09-19
US6465005B1 (en) 2002-10-15
EP1023055B1 (en) 2002-01-23

Similar Documents

Publication Publication Date Title
ES2172195T3 (es) Inhibicion de la cristalizacion en dispositivos transdermales.
AU741482B2 (en) Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CN101282701B (zh) 提供单纯孕激素避孕并将与之关联的不良副作用减到最小的制剂和方法
FI960556A (fi) Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä
ES2045153T3 (es) Metodo para la preparacion de formas de dosificacion de farmacos con liberacion sostenida que contienen hidroxi-propil-metilcelulosa y carboxilatos de metales alcalinos.
RU2700926C2 (ru) Трансдермальные системы, предотвращающие злоупотребление и неправильное употребление
WO2001052823A3 (en) Compositions to effect the release profile in the transdermal administration of drugs
AR064078A1 (es) Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
AU7465087A (en) Controlled release bioerodible drug delivery system
BRPI0518460A2 (pt) mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
CY1117127T1 (el) Συσκευη απονομης φαρμακευτικου υλικου
PT87936B (pt) Sistema de tratamento transdermico e sua utilizacao
CZ307857B6 (cs) Transdermální náplast pro podávání fentanylu nebo jeho analogu
DE69212497D1 (de) Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
AR076718A1 (es) Modulo medicinal con seleccion del usuario
AU2020200951B2 (en) Once-a-day replacement transdermal administration of fentanyl
AR048106A1 (es) Dispositivo de distribucion de drogas visible por rayos x
ES2068592T3 (es) Forma galenica inyectable retardada.
Mofidfar et al. Pharmaceutical jewelry: Earring patch for transdermal delivery of contraceptive hormone
BRPI0414471A (pt) nova formulação farmacêutica contendo biguanida e um derivado de tiazolidinadiona
KR101307650B1 (ko) 구역에 대한 경피 방법 및 패치
CO5261567A1 (es) Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas
CO5601036A2 (es) Composicion farmaceutica de liberacion sostenida
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1023055

Country of ref document: ES